1065 East Hillsdale Boulevard
Foster City, CA 94404
650 525 5535
Impiegati a tempo pieno: 41
|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Senthil Vel Sundaram||CEO & Director||850,2k||N/D||1978|
|Dr. Erin Quirk M.D.||Pres & Head of R&D||662,55k||N/D||1971|
|Mr. Seokho Yoon Esq.||COO, Gen. Counsel & Sec.||609,37k||N/D||1978|
|Dr. Weidong Zhong Ph.D.||Co-Founder & Exec. Officer||N/D||N/D||1966|
|Dr. Mark Joseph Vignola||CFO & Treasurer||N/D||N/D||1978|
|Dr. Jeffrey R. Jasper Ph.D.||Sr. VP & Head of Research||N/D||N/D||N/D|
|Ms. Diana Chung||Sr. VP & Chief Devel. Officer||N/D||N/D||N/D|
|Dr. Kerry Russell M.D., Ph.D.||Chief Medical Officer||N/D||N/D||N/D|
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
L'ISS Governance QualityScore di Terns Pharmaceuticals, Inc. al 1 febbraio 2023 è 8. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 8; diritti degli azionisti: 8; retribuzione: 8.